RESUMO

N-oxide derivatives 5(a-b), 8(a-b), and 11(a-c) were designed, synthesized and evaluated in vitro and in vivo as potential drugs that are able to ameliorate sickle cell disease (SCD) symptoms. All of the compounds demonstrated the capacity to releasing nitric oxide at different levels ranging from 0.8 to 30.1%, in vivo analgesic activity and ability to reduce TNF-α levels in the supernatants of monocyte cultures. The most active compound (8b) protected 50.1% against acetic acid-induced abdominal constrictions, while dipyrone, which was used as a control only protected 35%. Compounds 8a and 8b inhibited ADP-induced platelet aggregation by 84% and 76.1%, respectively. Both compounds increased γ-globin in K562 cells at 100 µM. The mechanisms involved in the γ-globin increase are related to the acetylation of histones H3 and H4 that is induced by these compounds. In vitro, the most promising compound (8b) was not cytotoxic, mutagenic and genotoxic.

Assuntos

Anemia Falciforme/tratamento farmacológico , Descoberta de Drogas , Histonas/metabolismo , Oxidiazóis/farmacologia , gama-Globinas/biossíntese , Ácido Acético/antagonistas & inibidores , Ácido Acético/farmacologia , Acetilação , Anemia Falciforme/metabolismo , Relação Dose-Resposta a Droga , Humanos , Células K562 , Estrutura Molecular , Óxido Nítrico/metabolismo , Oxidiazóis/síntese química , Oxidiazóis/química , Relação Estrutura-Atividade